SQuID方案(皮下胰岛素治疗糖尿病酮症酸中毒):临床医护人员接受度调查
该研究为横断面调查,于2023年3月至11月在一家城市学术医院开展,通过邮件向急诊和病房的护士及医生发放问卷,评估其对SQuID方案(皮下胰岛素治疗糖尿病酮症酸中毒)的接受度。总体应答率为80%(107/133),急诊医护人员中67%偏好SQuID而非静脉胰岛素,12%偏好静脉胰岛素,21%无偏好。各接受度领域的中位评分均为4分(IQR 4-5),正向应答(4分和5分)总体比例为92%,其中急诊护士89%、病房护士89%、急诊医生97%、病房医生87%。结论认为临床医护人员对SQuID方案接受度高,认为其易于使用、有效且公平。
要点
- SQuID方案(皮下胰岛素治疗糖尿病酮症酸中毒)在非ICU环境中用于低至中度严重程度的糖尿病酮症酸中毒患者。
- 急诊医护人员中67%偏好SQuID而非静脉胰岛素,12%偏好静脉胰岛素,21%无偏好(摘要结论部分写65%,原文此处表述有矛盾)。
- 总体应答率80%(107/133),其中急诊护士34/42、病房护士13/16、急诊医生47/57、病房医生13/17。
- 各接受度领域中位评分均为4分(IQR 4-5),正向应答总体比例为92%(急诊护士89%、病房护士89%、急诊医生97%、病房医生87%)。
- 首次使用SQuID的参与者比例从7.7%(住院医师)到35.3%(急诊护士)不等。
适用人群与场景
- 急诊护士和医生,以及病房护士和医生,这些人员正在治疗接受SQuID方案的患者。
- 研究对象为一家城市学术医院中治疗低至中度严重程度糖尿病酮症酸中毒患者的临床医护人员。
研究设计与关键结果
- 研究设计为横断面调查,于2023年3月至11月在一家城市学术医院开展,通过邮件调查链接发放问卷,临床医护人员只能填写一次。
- 总体应答率为80%(107/133),包括急诊护士34/42、病房护士13/16、急诊医生47/57、病房医生13/17。
- 首次使用SQuID的参与者比例从7.7%(住院医师)到35.3%(急诊护士)不等。
- 急诊医护人员偏好SQuID而非静脉胰岛素的比例为67%,偏好静脉胰岛素的比例为12%,无偏好的比例为21%。
- 各接受度领域和各类医护人员的中位评分均为4分(IQR 4-5)。
- 各领域正向应答(4分和5分)的总体比例为92%,其中急诊护士89%、病房护士89%、急诊医生97%、病房医生87%。
证据类型、等级与局限
- 证据类型:横断面研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: We previously implemented the SQuID protocol (subcutaneous insulin in diabetic ketoacidosis [DKA]) demonstrating safe, effective treatment of low- to moderate-severity DKA in a non-intensive care unit setting. Since success and sustainability of interventions rely on staff buy-in, we assessed acceptability of SQuID among emergency department (ED) and inpatient clinicians.
METHODS: We conducted a cross-sectional study in an urban academic hospital (March 2023-November 2023), surveying ED nurses (RNs) and physicians (MDs) and floor RNs and MDs treating patients on SQuID via emailed survey links. Clinicians could only take the survey once. We used Sekhon's Theoretical Framework of Acceptability, validated for staff acceptability of a new intervention, assessing eight domains with 5-point Likert responses. Clinicians were asked about prior experience with SQuID, and we assessed ED MD and RN preference (SQuID vs. intravenous [IV] insulin). Surveys included free-text boxes for comments. We present descriptive statistics including proportions with 95% confidence interval and medians with interquartile ranges (IQRs) and conducted thematic analysis of free-text comments.
RESULTS: Our overall response rate (107/133) was 80% (34/42 ED RNs, 13/16 floor RNs, 47/57 ED MDs, 13/17 floor MDs), with first-time users of SQuID ranging from 7.7% (hospitalist MDs) to 35.3% (ED RNs) of participants. ED clinicians preferred SQuID over IV insulin (67% vs. 12%, 21% no preference). Acceptability was high across all domains and clinician types (median 4, IQR 4-5). Overall percentage of positive responses (4s and 5s) across domains was 92% (ED RNs [89%], floor RNs [89%], ED MDs [97%], floor MDs [87%]). We identified several themes among participant comments.
CONCLUSIONS: Acceptability was high across clinician types; 65% of ED clinicians preferred SQuID to IV insulin. Clinicians liked SQuID (affective attitude), found it easy to use (burden), were confident in its use (self-efficacy), felt that it improved outcomes (perceived effectiveness), found that it was fair to patients (ethicality), found that it made sense (intervention coherence), and found that it did not interfere with other activities (opportunity cost).
参考来源
- Griffey RT, Schneider RM, Girardi M, et al. SQuID (subcutaneous insulin in diabetic ketoacidosis): Clinician acceptability. Acad Emerg Med. 2024. PMID: 39313955. doi:10.1111/acem.15019
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。